Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diverticulum, Colon | 1 | 2014 | 4 | 0.500 |
Why?
|
| Adenomatous Polyps | 1 | 2014 | 45 | 0.480 |
Why?
|
| Veterans | 4 | 2022 | 1641 | 0.460 |
Why?
|
| Colonic Polyps | 1 | 2014 | 209 | 0.410 |
Why?
|
| Colonoscopy | 1 | 2014 | 518 | 0.370 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 2027 | 0.350 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 242 | 0.340 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2011 | 184 | 0.330 |
Why?
|
| Duodenum | 2 | 2020 | 149 | 0.310 |
Why?
|
| Bronchoscopy | 3 | 2015 | 474 | 0.290 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 1390 | 0.270 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2023 | 489 | 0.260 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 4557 | 0.260 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2023 | 9 | 0.240 |
Why?
|
| Influenza, Human | 1 | 2011 | 925 | 0.230 |
Why?
|
| Lung | 3 | 2011 | 3151 | 0.230 |
Why?
|
| Mediastinal Diseases | 1 | 2003 | 56 | 0.230 |
Why?
|
| Rhabdomyoma | 1 | 2003 | 23 | 0.220 |
Why?
|
| Cell Degranulation | 1 | 2020 | 47 | 0.190 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2022 | 690 | 0.190 |
Why?
|
| Dyspepsia | 1 | 2020 | 103 | 0.180 |
Why?
|
| Eosinophils | 1 | 2020 | 162 | 0.180 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 2390 | 0.170 |
Why?
|
| Eosinophilia | 1 | 2020 | 176 | 0.160 |
Why?
|
| Barrett Esophagus | 2 | 2014 | 569 | 0.160 |
Why?
|
| Endoscopy, Digestive System | 2 | 2016 | 202 | 0.160 |
Why?
|
| Mouth Neoplasms | 1 | 2003 | 713 | 0.150 |
Why?
|
| Emphysema | 2 | 2009 | 87 | 0.150 |
Why?
|
| Precancerous Conditions | 2 | 2014 | 1058 | 0.150 |
Why?
|
| Celiac Disease | 1 | 2016 | 75 | 0.130 |
Why?
|
| Granuloma, Giant Cell | 1 | 2015 | 17 | 0.130 |
Why?
|
| Gout | 1 | 2015 | 31 | 0.130 |
Why?
|
| Salivary Glands, Minor | 1 | 2015 | 33 | 0.130 |
Why?
|
| Public Health Surveillance | 1 | 2015 | 63 | 0.130 |
Why?
|
| Middle Aged | 17 | 2022 | 86204 | 0.120 |
Why?
|
| Hernia, Hiatal | 1 | 2014 | 63 | 0.120 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2015 | 50 | 0.120 |
Why?
|
| Bone Marrow Diseases | 1 | 2015 | 177 | 0.120 |
Why?
|
| Klatskin Tumor | 1 | 2014 | 29 | 0.120 |
Why?
|
| Male | 21 | 2022 | 123000 | 0.120 |
Why?
|
| Biopsy, Needle | 4 | 2013 | 1363 | 0.120 |
Why?
|
| Leukocytosis | 1 | 2014 | 112 | 0.120 |
Why?
|
| Gastritis | 1 | 2017 | 373 | 0.110 |
Why?
|
| Splenic Neoplasms | 1 | 2014 | 119 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2014 | 829 | 0.110 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2014 | 334 | 0.110 |
Why?
|
| Image-Guided Biopsy | 1 | 2015 | 327 | 0.110 |
Why?
|
| Esophagoscopy | 1 | 2013 | 291 | 0.100 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 334 | 0.100 |
Why?
|
| Tracheal Neoplasms | 1 | 2012 | 42 | 0.100 |
Why?
|
| Carcinoma | 1 | 2023 | 2578 | 0.100 |
Why?
|
| Endosonography | 1 | 2015 | 536 | 0.100 |
Why?
|
| Debridement | 1 | 2012 | 123 | 0.100 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 234 | 0.100 |
Why?
|
| Neurilemmoma | 1 | 2012 | 127 | 0.100 |
Why?
|
| Overweight | 1 | 2014 | 484 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2015 | 717 | 0.090 |
Why?
|
| Humans | 25 | 2023 | 261506 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 7551 | 0.090 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 153 | 0.090 |
Why?
|
| Bile Duct Neoplasms | 1 | 2014 | 493 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2014 | 493 | 0.090 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 227 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 212 | 0.080 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 846 | 0.080 |
Why?
|
| Anemia | 1 | 2014 | 689 | 0.080 |
Why?
|
| Elastin | 1 | 2007 | 49 | 0.080 |
Why?
|
| Motor Activity | 1 | 2010 | 693 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2173 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2022 | 37905 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 451 | 0.070 |
Why?
|
| Autoimmunity | 1 | 2007 | 263 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2014 | 1216 | 0.060 |
Why?
|
| Smoking | 3 | 2014 | 2440 | 0.060 |
Why?
|
| Macrophages, Alveolar | 1 | 2004 | 67 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 2359 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2010 | 808 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2010 | 524 | 0.060 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2003 | 21 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2015 | 2967 | 0.060 |
Why?
|
| Gingiva | 1 | 2023 | 18 | 0.060 |
Why?
|
| Female | 11 | 2022 | 141928 | 0.060 |
Why?
|
| Aged | 11 | 2020 | 70117 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2009 | 1085 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2004 | 250 | 0.060 |
Why?
|
| Pulmonary Emphysema | 1 | 2004 | 145 | 0.060 |
Why?
|
| Fiber Optic Technology | 1 | 2003 | 142 | 0.060 |
Why?
|
| Lymphangioma | 1 | 2003 | 36 | 0.060 |
Why?
|
| Logistic Models | 2 | 2014 | 3441 | 0.050 |
Why?
|
| Lymphatic Metastasis | 3 | 2023 | 4844 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2023 | 209 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 849 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 195 | 0.050 |
Why?
|
| Hemangioma | 1 | 2003 | 154 | 0.050 |
Why?
|
| Breast Neoplasms, Male | 1 | 2002 | 229 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 3168 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 7548 | 0.050 |
Why?
|
| Mediastinal Neoplasms | 1 | 2003 | 423 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 13658 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2007 | 1021 | 0.040 |
Why?
|
| Sex Factors | 2 | 2014 | 2139 | 0.040 |
Why?
|
| Prevalence | 2 | 2017 | 3260 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2020 | 9244 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 755 | 0.040 |
Why?
|
| United States | 4 | 2020 | 15433 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2232 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 1245 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2013 | 2316 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 4314 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 7789 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 1323 | 0.030 |
Why?
|
| Uric Acid | 1 | 2015 | 75 | 0.030 |
Why?
|
| Ethmoid Bone | 1 | 2015 | 14 | 0.030 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 29902 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2014 | 59 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2016 | 250 | 0.030 |
Why?
|
| Maxilla | 1 | 2015 | 84 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2016 | 397 | 0.030 |
Why?
|
| Adult | 7 | 2017 | 77950 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 10331 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 4744 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 120 | 0.030 |
Why?
|
| Risk Factors | 3 | 2017 | 17523 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 11538 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 756 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 249 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 980 | 0.020 |
Why?
|
| Coffee | 1 | 2010 | 33 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 3343 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 4892 | 0.020 |
Why?
|
| Time Factors | 2 | 2014 | 12926 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 2576 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 2231 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2013 | 667 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 14889 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2010 | 235 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2009 | 284 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1945 | 0.020 |
Why?
|
| Equipment Design | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 620 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2015 | 2358 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 3443 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 256 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 1162 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 3890 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3981 | 0.020 |
Why?
|
| Registries | 1 | 2014 | 2170 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2009 | 1681 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 2014 | 1295 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2004 | 36 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2004 | 105 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 137 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 114 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 117 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 5673 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 5377 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2007 | 673 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2002 | 119 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 1294 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2013 | 6869 | 0.010 |
Why?
|
| Inflammation | 1 | 2010 | 2522 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2002 | 666 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 2961 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5687 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 10035 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2002 | 2084 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 2809 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 4298 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2007 | 3869 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 6682 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 8873 | 0.000 |
Why?
|
| Adolescent | 1 | 2002 | 31252 | 0.000 |
Why?
|